ArticleDiscover oncology2025
DNA methylation-mediated ADA overexpression drives pancreatic cancer progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) is characterized by its aggressive nature, limited options for radiochemotherapy, and poor prognosis, highlighting the urgent need for the identification of novel therapeutic targets to broaden treatment strategies.
methodsWe employed a two-sample Mendelian randomization (MR) approach, utilizing genetically informed druggable genes to identify key genes associated with PC risk. To validate these candidate targets, we conducted sensitivity, colocaliztion, and summary data-based MR (SMR) analyses. Furthermore, DNA methylation mediation analysis was utilized to investigate upstream regulatory mechanisms of significant genes.
resultsAt a false discovery rate (FDR) of less than 0.05, five druggable genes were found to be significantly associated with PC. Through rigorous validation, adenosine deaminase (ADA) was identified as a potential contributor to increased PC risk. Mediation analysis indicated that higher methylation at cg20622019 was associated with lower ADA expression and reduced PC risk, with methylation mediating approximately 36% of the association between ADA and PC. Sensitivity analysis, SMR and Colocalization analysis supported our findings, demonstrating high statistical robustness.
conclusionThis study identifies ADA as a prioritized, genetically supported druggable target for PC, supported by colocalization evidence (PPH4 = 0.7949), and elucidates the regulatory role of DNA methylation at the cg20622019 locus. Notably, other significantly screened genes (e.g., PDE2A) failed colocalization validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.